Search results for: HTA
Filter search results
Cost-per-QALY in the US and Britain: Damned if You Do and Damned if You Don’t
1 December 2015
Professor Weinstein presents a comprehensive analysis of the differences in attitudes between the US and the UK around how cost-effectiveness analysis (CEA) fits into the health care system. Professor Weinstein…
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
4 January 2016
This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and…
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
1 December 2016
This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and interviews involving people from…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The purpose of this OHE…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and value. Special attention is…
Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
1 March 2018
The report addresses the implications of NICE appraising treatments for very rare diseases using a cost-per-QALY gained decision rule of the type used by NICE in its Technology Appraisal Programme…
Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
1 August 2018
This OHE Research paper by Karla Hernandez-Villafuerte, (German Cancer Research Center, DKFZ), Bernarda Zamora (OHE) and Adrian Towse (OHE) sets out a research agenda proposing new approaches in three areas…
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available publicly. This is exciting,…
The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
1 August 2020
Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this perspective,…